191 related articles for article (PubMed ID: 18300947)
1. Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis.
Shukla SJ; Duan S; Badner JA; Wu X; Dolan ME
Pharmacogenet Genomics; 2008 Mar; 18(3):253-62. PubMed ID: 18300947
[TBL] [Abstract][Full Text] [Related]
2. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.
Dolan ME; Newbold KG; Nagasubramanian R; Wu X; Ratain MJ; Cook EH; Badner JA
Cancer Res; 2004 Jun; 64(12):4353-6. PubMed ID: 15205351
[TBL] [Abstract][Full Text] [Related]
3. Mapping genes that contribute to daunorubicin-induced cytotoxicity.
Duan S; Bleibel WK; Huang RS; Shukla SJ; Wu X; Badner JA; Dolan ME
Cancer Res; 2007 Jun; 67(11):5425-33. PubMed ID: 17545624
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide discovery of loci influencing chemotherapy cytotoxicity.
Watters JW; Kraja A; Meucci MA; Province MA; McLeod HL
Proc Natl Acad Sci U S A; 2004 Aug; 101(32):11809-14. PubMed ID: 15282376
[TBL] [Abstract][Full Text] [Related]
5. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach.
Huang RS; Duan S; Shukla SJ; Kistner EO; Clark TA; Chen TX; Schweitzer AC; Blume JE; Dolan ME
Am J Hum Genet; 2007 Sep; 81(3):427-37. PubMed ID: 17701890
[TBL] [Abstract][Full Text] [Related]
6. Whole-genome approach implicates CD44 in cellular resistance to carboplatin.
Shukla SJ; Duan S; Wu X; Badner JA; Kasza K; Dolan ME
Hum Genomics; 2009 Jan; 3(2):128-42. PubMed ID: 19164090
[TBL] [Abstract][Full Text] [Related]
7. Identification of genomic regions contributing to etoposide-induced cytotoxicity.
Bleibel WK; Duan S; Huang RS; Kistner EO; Shukla SJ; Wu X; Badner JA; Dolan ME
Hum Genet; 2009 Mar; 125(2):173-80. PubMed ID: 19089452
[TBL] [Abstract][Full Text] [Related]
8. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity.
Huang RS; Duan S; Bleibel WK; Kistner EO; Zhang W; Clark TA; Chen TX; Schweitzer AC; Blume JE; Cox NJ; Dolan ME
Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9758-63. PubMed ID: 17537913
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.
Wen Y; Gorsic LK; Wheeler HE; Ziliak DM; Huang RS; Dolan ME
Pharmacogenet Genomics; 2011 Aug; 21(8):476-88. PubMed ID: 21642893
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants contributing to daunorubicin-induced cytotoxicity.
Huang RS; Duan S; Kistner EO; Bleibel WK; Delaney SM; Fackenthal DL; Das S; Dolan ME
Cancer Res; 2008 May; 68(9):3161-8. PubMed ID: 18451141
[TBL] [Abstract][Full Text] [Related]
11. Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies.
Shukla SJ; Dolan ME
Pharmacogenomics; 2005 Apr; 6(3):303-10. PubMed ID: 16013961
[TBL] [Abstract][Full Text] [Related]
12. Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy.
Stark AL; Hause RJ; Gorsic LK; Antao NN; Wong SS; Chung SH; Gill DF; Im HK; Myers JL; White KP; Jones RB; Dolan ME
PLoS Genet; 2014 Apr; 10(4):e1004192. PubMed ID: 24699359
[TBL] [Abstract][Full Text] [Related]
13. Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants.
O'Donnell PH; Gamazon E; Zhang W; Stark AL; Kistner-Griffin EO; Stephanie Huang R; Eileen Dolan M
Pharmacogenet Genomics; 2010 May; 20(5):327-37. PubMed ID: 20393316
[TBL] [Abstract][Full Text] [Related]
14. Linkage analysis using platelet-activating factor Ca2+ response in transformed lymphoblasts.
Brzustowicz LM; Gardner JP; Hopp L; Jeanclos E; Ott J; Yang XY; Fekete Z; Aviv A
Hypertension; 1997 Jan; 29(1 Pt 2):158-64. PubMed ID: 9039096
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans.
Wheeler HE; Gorsic LK; Welsh M; Stark AL; Gamazon ER; Cox NJ; Dolan ME
PLoS One; 2011; 6(7):e21920. PubMed ID: 21755009
[TBL] [Abstract][Full Text] [Related]
16. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
17. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines.
Stark AL; Zhang W; Mi S; Duan S; O'Donnell PH; Huang RS; Dolan ME
Pharmacogenomics J; 2010 Dec; 10(6):505-12. PubMed ID: 20142840
[TBL] [Abstract][Full Text] [Related]
18. CEPH individuals are representative of the European American population: implications for pharmacogenetics.
Meucci MA; Marsh S; Watters JW; McLeod HL
Pharmacogenomics; 2005 Jan; 6(1):59-63. PubMed ID: 15723606
[TBL] [Abstract][Full Text] [Related]
19. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity.
Hartford CM; Duan S; Delaney SM; Mi S; Kistner EO; Lamba JK; Huang RS; Dolan ME
Blood; 2009 Mar; 113(10):2145-53. PubMed ID: 19109566
[TBL] [Abstract][Full Text] [Related]
20. Linkage and association analyses of principal components in expression data.
Hinrichs AL; Culverhouse R; Jin CH; Suarez BK
BMC Proc; 2007; 1 Suppl 1(Suppl 1):S46. PubMed ID: 18466545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
